Skip to content
DE

Slippery elm: what elm bark can do for the throat and gut

Clinical review pending

Mucilage from red elm forms a gel. How to weigh this mechanism and what studies show for irritable bowel syndrome and reflux.

Slippery elm contains mucilage, compounds that form a thick gel with water. That makes temporary relief of irritated mucous membranes plausible. Direct research on slippery elm as a stand-alone treatment for irritable bowel syndrome, reflux or inflammatory bowel disease is thin, however. Most clinical results come from blends, and their effect cannot be pinned on any single ingredient.

What is slippery elm?

Slippery elm is the dried inner bark of the red elm, botanically Ulmus rubra. The tree is native to eastern North America. The powder contains branched carbohydrate chains that bind water and form a gel. The foundational chemical description of this mucilage dates back to 1946.

Inner elm bark is one of the so-called demulcents: substances meant to soothe irritated surfaces by coating them with a protective film. A US OTC monograph for oral and throat care products lists it for this limited use. That is not a general confirmation that it works for gut complaints.

What mucilage is

The mucilage contains building blocks such as rhamnose, galacturonic acid and galactose. Once it takes up water, its consistency changes. The gel formation of plant mucilages sets them apart from, for example, mostly insoluble fibers such as wheat bran.

What a fiber does is not determined by solubility alone. Viscosity and fermentability also shape how it behaves in the gut. Reviews of fiber physiology, of plant mucilages and of their properties help put these differences in context. Results for one fiber therefore cannot simply be carried over to any other.

Origin and traditional use

The part used is the inner bark, which is dried and ground. A historical report from 1845 describes elm bark used for medical dilators. A long history of use is no substitute for modern testing of efficacy and safety.

Today there are powders, capsules, lozenges and ready-mixed preparations. A clear statement that the product is Ulmus rubra and inner bark is helpful. Traceable origin and gentle harvesting also matter, because elms are under pressure from Dutch elm disease and stripping bark can damage the trees.

How elm bark might work in the body

A film on the mucous membrane

The gel can come into contact with surfaces in the mouth, throat and digestive tract. The idea is that a temporary film reduces direct contact with irritating substances. Reduced irritation of sensitive nerve endings has also been proposed, for instance in a paper on herbal approaches to functional gut disorders.

Some of the mechanistic research concerns other substances. In a model using esophageal tissue, electrical tissue resistance under acid exposure fell by 8.3 percent with alginate and by 25.1 percent in the control condition. This resistance serves as a measure of barrier function. Studies on cashew gum and lemon gum also examined protective mechanisms. None of these figures describes a clinically proven effect of elm bark in humans.

Mostly local action

The large mucilage molecules are not fully absorbed the way an ordinary drug is. Gut bacteria can ferment certain components, producing short-chain fatty acids among other things. How much of this happens with a particular elm bark preparation, and what clinical benefit it brings, has been studied less well than the general metabolism of soluble fibers.

Gel formation could also affect the absorption of medications taken at the same time. Older and more recent reviews of interactions provide general context for this. A gap of 1–2 hours is often suggested. A particular medication may need a different gap; a pharmacist can check this against the specific products.

How well each use has been studied

Irritated throat: support for the protective mechanism

Lozenge studies examine various approaches to short-term relief of sore throat, including the anti-inflammatory drug flurbiprofen. They include studies on onset of action, on sore throat products, further controlled data and a more recent paper. The effect of pure elm bark cannot be inferred from these results: the active drug and the lozenge base have to be considered separately.

Irritable bowel syndrome: small studies with several ingredients

A pilot study of 31 people with irritable bowel syndrome tested blends that included elm bark, lactulose, bilberry, agrimony and cinnamon, among other ingredients. Some symptoms, such as straining, pain and bloating, improved. Which ingredient contributed remains open.

In a 16-week study of 43 adults, the blend contained curcumin, aloe, elm bark, guar gum, pectin, peppermint and glutamine. Reductions in gastrointestinal symptoms of 60–80 percent were reported. That is a result for the whole approach studied, not an efficacy rate for slippery elm.

A systematic review of Western herbal preparations shows how rarely such findings have been replicated. For other soluble fibers, especially psyllium, the clinical basis is broader: there are older controlled trials, a network meta-analysis of 51 studies and an AGA recommendation on diet in irritable bowel syndrome. A recommendation for soluble fiber is not automatically a recommendation for elm bark in particular.

Reflux: a plausible idea, little direct clinical data

The models with alginate and other mucilages described above explain why a protective film could be interesting. A critical review of popular remedies for esophageal symptoms places elm bark in this context. None of this provides reliable proof that elm bark alone treats gastroesophageal reflux disease.

Crohn’s disease and ulcerative colitis: no substitute for treatment

A review of herbal remedies for active ulcerative colitis and a paper on complementary therapies show how varied the approaches studied are. Elm bark is not an established treatment for inducing or maintaining remission. It replaces neither control of the inflammation nor effective medication.

Promises that elm bark alone can heal a “leaky gut” or detox the bowel also go beyond the data. Possible short-term soothing of symptoms is something different from curing an underlying disease.

Forms and quality

Powder is often stirred into water; capsules and lozenges differ in where, and for how long, their contents come into contact with mucous membranes. A highly concentrated extract is not automatically better if what matters is precisely the physical properties of the intact mucilage.

Helpful signs are a clear statement of the plant and the bark, traceable batch testing and information on contaminants. Seals such as USP or NSF can confirm certain aspects of quality, provided they actually apply to the specific product. A certificate of analysis should make clear what was tested. Neither a quality seal nor a high stated mucilage content proves that a product treats a disease.

What the regulatory status means

In the United States, many elm bark products are sold as dietary supplements. Separately, the FDA monograph mentioned above sets requirements for certain over-the-counter throat products. These categories need to be kept apart. A monograph does not mean that any given supplement is individually approved, nor does it confirm every marketing claim.

What counts for assessing this is the specific monograph and the jurisdiction in question. Even with a product statement dated May 2026, you still need to check whether it is current and applies to the specific product. For competitive sport, too, checking the specific product as it is now matters more than a blanket reference to a prohibited list.

Safety and interactions

Possible side effects

Bloating or loose stools are possible with fiber-rich preparations, especially if the amount is increased quickly. Allergic reactions are also conceivable. The limited number of clinical studies does not allow a complete picture of rare side effects. The fact that no characteristic liver injury has been described does not mean that every product and every use has been thoroughly studied.

Medications and timing

A mucilage gel could delay or alter the absorption of medications taken by mouth. Combining it with levothyroxine, or with drugs that have a narrow therapeutic range such as warfarin or lithium, should be checked especially carefully. The often-cited gap of 1–2 hours is no guarantee that every interaction is ruled out.

With diabetes medications, a possible effect of soluble fiber on blood sugar is also under discussion. For elm bark itself, solid data on the size of this interaction are lacking. The pharmacokinetic review offers a framework for advice, not individual dosing instructions.

Pregnancy, breastfeeding and special situations

Controlled safety data for pregnancy and breastfeeding are scarce. Deliberate use should therefore be discussed with your care team. The same applies to relevant liver or kidney disease. For young children, especially under 2 years, suitable data on powder preparations are lacking; product requirements for certain throat remedies must not be transferred to arbitrary blends.

Who should avoid elm bark or check first

Anyone with a known elm allergy should avoid the product. During pregnancy and breastfeeding, for young children, with active inflammatory bowel disease and while taking medications whose absorption is sensitive, it makes sense to ask first. Ongoing treatments should not be interrupted to try elm bark.

Which tests can be useful for gut complaints

There is no established blood marker that measures the effect of a mucilage film. Tests therefore depend on the symptoms: fecal calprotectin can help when gut inflammation is suspected; a blood count, ferritin and transferrin saturation are options when anemia or blood loss is possible. hs-CRP is a nonspecific marker of inflammation. HbA1c and fasting glucose answer questions about sugar metabolism, not about whether elm bark works.

A routine before-and-after panel at 8–12 weeks is not established for this purpose. Nor can a lower inflammation value or a higher ferritin level simply be credited to the supplement. What matters is whether a specific test changes the diagnosis or the treatment.

When symptoms need more than a herbal remedy

Persistent or worsening reflux, difficulty swallowing, blood in the stool, unexplained weight loss or long-standing gut complaints deserve medical investigation. Depending on the findings, targeted reflux therapy, treatment for irritable bowel syndrome or further diagnostic tests may be appropriate. Papers on reflux treatment, diet in irritable bowel syndrome and inflammatory bowel disease provide the clinical framework for this. A pleasant short-term effect must not mask warning signs like these.

Frequently asked questions

What exactly is slippery elm?

It is the inner bark of Ulmus rubra. Its mucilage forms a gel with water. Powders, capsules and lozenges are not automatically interchangeable preparations.

Does elm bark really work?

A soothing film on irritated mucous membranes is plausible and fits the use of certain throat products. For gut diseases, many of the positive results come from blends. The US rule on OTC ingredients also has to be read in the context of the specific product category.

What amounts have been used?

For preparations, 400 mg to 1.5 g per dose, taken 1–3 times a day, is often cited. From its abstract, however, the IBS pilot study does not allow a reliable isolated dose of elm bark to be identified. No generally effective or optimal dose can be derived from this.

What side effects are possible?

Possible side effects include bloating, loose stools and allergic reactions. The absorption of medications taken at the same time should also be considered. Safety data on rare events and long-term use are limited.

Is slippery elm FDA-approved?

An ordinary dietary supplement does not gain general drug approval because of its ingredient. The inner bark is named in an OTC monograph for certain throat uses. That is a limited regulatory framework.

Is elm bark the same as marshmallow root?

No. Both contain mucilage, but they come from different plants and differ in composition. Results for one plant do not automatically confirm the effect of the other.

Can there be interactions?

The absorption of medications taken by mouth could be affected. A gap of 1–2 hours is often cited, but it should be checked for your specific medication. If irritable bowel syndrome is suspected, a guideline-based workup helps more than switching between products without guidance.

Do you need blood tests first?

Not routinely, just to try elm bark. With persistent symptoms, targeted blood or stool tests can be useful. Their purpose is to find the underlying cause, not to measure an unconfirmed supplement effect with a large lab panel.

Sources

  • GILL RE, HIRST EL, JONES JK (1946). Constitution of the mucilage from the bark of Ulmus fulva (slippery elm mucilage); the sugars formed in the hydrolysis of the methylated mucilage. Journal of the Chemical Society, 1025-9. https://doi.org/10.1039/jr9460001025

  • U.S. Food and Drug Administration. (2022). Oral healthcare drug products for over-the-counter human use (OTC Monograph M022). U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M022-Oral%20Healthcare%20Products%20for%20OTC%20human%20Use%2010.14.2022.pdf

  • Olawuyi IF, Kim SR, Lee WY (2021). Application of plant mucilage polysaccharides and their techno-functional properties’ modification for fresh produce preservation. Carbohydrate polymers, 272, 118371. https://doi.org/10.1016/j.carbpol.2021.118371

  • Currò D (2022). Current evidence on the therapeutic use of fiber in irritable bowel syndrome. Expert review of gastroenterology & hepatology, 16(5), 425-436. https://doi.org/10.1080/17474124.2021.1924057

  • Gill SK, Rossi M, Bajka B, Whelan K (2021). Dietary fibre in gastrointestinal health and disease. Nature reviews. Gastroenterology & hepatology, 18(2), 101-116. https://doi.org/10.1038/s41575-020-00375-4

  • Tsai AY, McGee R, Dean GH, Haughn GW, Sawa S (2021). Seed Mucilage: Biological Functions and Potential Applications in Biotechnology. Plant & cell physiology, 62(12), 1847-1857. https://doi.org/10.1093/pcp/pcab099

  • Herrick WB (1845). On Bougies of Slippery Elm Bark. Western journal of medicine and surgery, 4(5), 433-434. https://pubmed.ncbi.nlm.nih.gov/38208821/

  • Lashgari NA, Roudsari NM, Momtaz S, Niazi Shahraki F, Zandi N, Pazoki B, Farzaei MH, Ghasemi M, Abdollahi M, Abdolghaffari AH (2024). Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders. Current pharmaceutical biotechnology, 25(13), 1632-1650. https://doi.org/10.2174/0113892010261502231102040149

  • Woodland P, Batista-Lima F, Lee C, Preston SL, Dettmar P, Sifrim D (2015). Topical protection of human esophageal mucosal integrity. American journal of physiology. Gastrointestinal and liver physiology, 308(12), G975-80. https://doi.org/10.1152/ajpgi.00424.2014

  • Nicolau LAD, Batista-Lima FJ, Santana APM, Sales TMAL, Carmo-Neto JP, Freitas GB, Oliveira TM, Medeiros JVR, Silva DA, Lee C, Woodland PJ, Soares PMG, Vale ML, Santos AA, Sifrim D, Souza MHLP (2019). Cashew gum, a biopolymer, topically protects oesophageal mucosa in non erosive reflux disease: A promising translational study. Carbohydrate polymers, 226, 115205. https://doi.org/10.1016/j.carbpol.2019.115205

  • Teixeira LFSL, Silva KC, Ribeiro FOS, da Silva AP, Nascimento RR, Souza LP, Franco, Á. X., Jacumazo J, Lima LJ, de Araujo-Nobre AR, Vale ML, Souza MHLP, Palumbo-Junior A, Freitas RA, Medeiros JVR, Cordeiro LMC, Silva DA, Nicolau LAD (2025). Lemon gum blankets esophageal mucosa and promotes therapeutic effects in experimental models of gastroesophageal reflux disease: Grasps for prevention and treatment. Carbohydrate polymers, 370, 124485. https://doi.org/10.1016/j.carbpol.2025.124485

  • Fugh-Berman A (2000). Herb-drug interactions. Lancet (London, England), 355(9198), 134-8. 06457-0). https://doi.org/10.1016/S0140-6736(99)06457-0

  • Cheng W, Xia K, Wu S, Li Y (2023). Herb-Drug Interactions and Their Impact on Pharmacokinetics: An Update. Current drug metabolism, 24(1), 28-69. https://doi.org/10.2174/1389200224666230116113240

  • Schachtel B, Aspley S, Shephard A, Shea T, Smith G, Sanner K, Savino L, Rezuke J, Schachtel E (2014). Onset of action of a lozenge containing flurbiprofen 8.75 mg: a randomized, double-blind, placebo-controlled trial with a new method for measuring onset of analgesic activity. Pain, 155(2), 422-428. https://doi.org/10.1016/j.pain.2013.11.001

  • Benrimoj SI, Langford JH, Christian J, Charlesworth A, Steans A (2001). Efficacy and Tolerability of the Anti-inflammatory Throat Lozenge Flurbiprofen 8.75mg in the Treatment of Sore Throat : A Randomised, Double-Blind, Placebo-Controlled Study. Clinical drug investigation, 21(3), 183-93. https://doi.org/10.2165/00044011-200121030-00004

  • Watson N, Nimmo WS, Christian J, Charlesworth A, Speight J, Miller K (2000). Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety. International journal of clinical practice, 54(8), 490-6. https://pubmed.ncbi.nlm.nih.gov/11198725/

  • Hawrelak JA, Myers SP (2010). Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study. Journal of alternative and complementary medicine (New York, N.Y.), 16(10), 1065-71. https://doi.org/10.1089/acm.2009.0090

  • Ried K, Travica N, Dorairaj R, Sali A (2020). Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders. Nutrition research (New York, N.Y.), 76, 37-51. https://doi.org/10.1016/j.nutres.2020.02.008

  • Hawrelak JA, Wohlmuth H, Pattinson M, Myers SP, Goldenberg JZ, Harnett J, Cooley K, Van De Venter C, Reid R, Whitten DL (2020). Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Complementary therapies in medicine, 48, 102233. https://doi.org/10.1016/j.ctim.2019.102233

  • Prior A, Whorwell PJ (1987). Double blind study of ispaghula in irritable bowel syndrome. Gut, 28(11), 1510-3. https://doi.org/10.1136/gut.28.11.1510

  • Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, Ford AC (2020). Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. The lancet. Gastroenterology & hepatology, 5(2), 117-131. 30324-3). https://doi.org/10.1016/S2468-1253(19)30324-3

  • Chey WD, Hashash JG, Manning L, Chang L (2022). AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review. Gastroenterology, 162(6), 1737-1745.e5. https://doi.org/10.1053/j.gastro.2021.12.248

  • Ahuja A, Ahuja NK (2019). Popular Remedies for Esophageal Symptoms: a Critical Appraisal. Current gastroenterology reports, 21(8), 39. https://doi.org/10.1007/s11894-019-0707-4

  • Iyengar P, Godoy-Brewer G, Maniyar I, White J, Maas L, Parian AM, Limketkai B (2024). Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Nutrients, 16(7). https://doi.org/10.3390/nu16070934

  • Şen A (2022). Complementary medicines used in ulcerative colitis and unintended interactions with cytochrome P450-dependent drug-metabolizing enzymes. Turkish journal of medical sciences, 52(5), 1425-1447. https://doi.org/10.55730/1300-0144.5482

  • U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://accessdata.fda.gov/scripts/cder/daf

  • Ford AC, Sperber AD, Corsetti M, Camilleri M (2020). Irritable bowel syndrome. Lancet (London, England), 396(10263), 1675-1688. 31548-8). https://doi.org/10.1016/S0140-6736(20)31548-8

  • Drugs for human use; drug efficacy study implementation; conditions under which the over-the-counter drugs are generally recognized as not safe and effective or are misbranded, 21 C.F.R. § 310.545 (n.d.). https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-310/subpart-G/section-310.545

  • Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. The American journal of gastroenterology, 116(1), 17-44. https://doi.org/10.14309/ajg.0000000000001036